Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An NIS Registry for the Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic NSCLC (Stage IIIB/IV Non-small Cell Lung Cancer)-REASON STUDY.

NCT01153399 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01153399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01153399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An NIS Registry for the Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic NSCLC (Stage IIIB/IV Non-small Cell Lung Cancer)-REASON STUDY.
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
October 31, 2010
Completion date
December 31, 2014
Enrollment
589 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer